E2 Scales Innovation in VTE Treatment
Endovascular Engineering, Inc. (“E2”), a commercial-stage medical technology company, announced an oversubscribed $80 million Series C funding round. The financing was co-led by Gilde Healthcare and Norwest. Existing investors including Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, and M&L Healthcare Investments participated. Two undisclosed strategic investors and a new global strategic partner also joined.
The funding will accelerate commercialisation of E2’s Hēlo® Thrombectomy Platform. The platform treats pulmonary embolism (PE), the third leading cause of cardiovascular death globally. PE often presents rapidly and can be fatal without timely intervention. Traditional treatment options are limited and sometimes ineffective. E2’s technology aims to provide physicians with a more efficient, precise alternative.
The Hēlo® Platform was designed to overcome the limitations of legacy thrombectomy systems. Its patented dual-action mechanism integrates aspiration with mechanical clot disruption. Using a small-profile catheter, the system delivers large-bore performance. This allows physicians to complete procedures in a single pass, reducing procedural time and patient risk.
E2 says the platform also improves procedural consistency. By integrating multiple functions into a single device, clinicians can focus more on patient outcomes. The system supports the growing adoption of mechanical thrombectomy as a safe and effective method for treating PE.
Strategic Support and Board Expansion
“This is a pivotal milestone for E2,” said Dan Rose, CEO. “This financing allows us to scale our commercial organisation while continuing investments in R&D and operations.”
Gilde Healthcare’s Geoff Pardo emphasised the platform’s potential impact. “E2 represents the kind of innovation that advances clinical care and could define a category,” he said. Pardo previously led Inari Medical’s Series C funding, which resulted in a successful acquisition by Stryker. His return to the VTE space reflects strong conviction in E2’s approach.
Norwest’s Zack Scott, M.D., highlighted the urgent need for better PE treatments. “Pulmonary embolism remains a complex and life-threatening condition. E2’s technology positions the Hēlo® Platform as a preferred solution,” he said.
Both Pardo and Scott will join E2’s Board. They will guide the next phase of growth and commercial expansion. Their experience in healthcare investment is expected to accelerate adoption of the Hēlo® Platform across hospitals and specialised centres.
Hēlo® Platform Advances Clinical Outcomes
The Hēlo® Thrombectomy System allows non-surgical removal of emboli and thrombi. It supports aspiration, injection, and infusion of contrast media and fluids. The system is intended for use in peripheral veins and pulmonary arteries.
By integrating mechanical and aspirational clot removal, the system enhances procedural efficiency. Physicians can remove larger clots faster and with fewer complications. This reduces the risk associated with multi-pass procedures and shortens time under anaesthesia.
E2 says Hēlo® is designed with both physicians and patients in mind. The platform combines clinical performance with operational simplicity. Training requirements are streamlined, allowing interventional teams to adopt the technology quickly.
The Hēlo® system positions E2 alongside established thrombectomy players, including Stryker, Boston Scientific, Imperative Care, Inquis Medical, and Jupiter Endovascular. While competitors focus on incremental improvements, E2 says Hēlo® offers a new standard for efficiency and patient care.
Commercial Expansion and Market Impact
E2 leverages Series C funding to expand hospital adoption of its Hēlo® Platform, enhancing PE treatment efficiency and clinical outcomes globally. Source: Created by Ventureburn.
The Series C funds will allow E2 to expand its commercial footprint in North America and internationally. Investments will also support research and development efforts. The company intends to strengthen sales and marketing teams to reach more hospitals and specialised treatment centres.
E2’s technology could reshape the PE treatment landscape. Mechanical thrombectomy has grown rapidly as hospitals seek faster, more effective interventions. With the Hēlo® Platform, clinicians can adopt a unified device that simplifies workflow and improves outcomes.
The funding signals confidence from investors in both the technology and E2’s team. Gilde and Norwest bring experience in scaling healthcare companies. Additional strategic investors will further enhance the company’s global reach and strategic partnerships.
E2 plans to continue building a robust commercial organisation. The company will recruit additional personnel for operations, regulatory support, and customer success teams. Investments in training and support aim to maximise adoption and clinical success of the Hēlo® Platform.
Industry analysts suggest that PE treatment is entering a new era. Mechanical thrombectomy is increasingly recognised as a reliable alternative to thrombolysis and open surgical approaches. E2 aims to set the standard for future thrombectomy devices.
The Hēlo® Platform may also reduce hospital costs and procedure times. By enabling single-pass clot removal, hospitals can optimise workflow. Clinicians can treat more patients safely and efficiently.
More News: Natter Raises $23M to Scale AI Conversation Platform for Enterprise Insights
Investment Reflects Sector Confidence
Gilde Healthcare’s investment marks a strategic return to the VTE market. The firm previously supported Inari Medical, which achieved a successful exit through Stryker. Their continued focus on innovative PE solutions demonstrates sector confidence in E2’s technology and market potential.
Norwest also cited E2’s strong leadership team as a key factor. The company’s commercial strategy and operational planning indicate readiness for rapid scaling. Investors expect the Hēlo® Platform to become a key tool in pulmonary embolism treatment worldwide.
E2 says adoption will initially target high-volume PE centres. Over time, hospitals of all sizes may integrate the platform. By combining safety, efficiency, and simplicity, the Hēlo® Platform could redefine standard care for VTE patients.
To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.
